To explore the safety and effectiveness of surgery after treatment with induced anti-PD-L1 antibody (TQB2450) therapy and chemotherapy in patients with stage I‒III SCLC, we performed this phase II trial (LungMate-005). The gene discussed is CD274; the disease is small cell lung carcinoma.